Rafael Bejar, Ph.D.
Affiliations: | 2001 | University of California, San Diego, La Jolla, CA |
Area:
MemoryGoogle:
"Rafael Bejar"Mean distance: 13.61 (cluster 29) | S | N | B | C | P |
Parents
Sign in to add mentor| Larry R. Squire | grad student | 2001 | UCSD | |
| (Genetic manipulations of synaptic plasticity, learning, and memory: Findings from calcium/calmodulin-dependent protein kinase II and K(v)4.2 transgenic mice.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| DeZern AE, Goll JB, Lindsley RC, et al. (2023) Utility of Targeted Gene Sequencing to Differentiate Myeloid Malignancies from other Cytopenic Conditions. Blood Advances |
| Huang YJ, Chen JY, Yan M, et al. (2022) RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS. Blood Advances |
| Bernard E, Nannya Y, Hasserjian RP, et al. (2020) Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine |
| Malcovati L, Stevenson K, Papaemmanuil E, et al. (2020) SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). Blood |
| Park SJ, Bejar R. (2020) Clonal Hematopoiesis in Cancer. Experimental Hematology |
| Pine AB, Chokr N, Stahl M, et al. (2020) Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leukemia & Lymphoma. 1-10 |
| Bejar R. (2019) Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 1444-1447 |
| Reilly B, Tanaka TN, Diep D, et al. (2019) DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes. Blood Advances. 3: 2845-2858 |
| Stoner SA, Yan M, Liu KTH, et al. (2019) Hippo Kinase Loss Contributes to Del(20q) Hematologic Malignancies through Chronic Innate Immune Activation. Blood |
| Bell JA, Galaznik A, Pompilus F, et al. (2019) A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Journal of Patient-Reported Outcomes. 3: 35 |